Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Ribas

Showing results (21-30 of 467) with videos related to

Pageof 47
Sort By:
The Journal of Pathology|September 13, 2013
New drug targets in metastatic melanomaBlanca Homet, Antoni Ribas
Nature Reviews. Immunology|October 2, 2019
Tumour-intrinsic resistance to immune checkpoint blockadeAnusha Kalbasi, Antoni Ribas
European Urology|February 10, 2009
Editorial comment on: Vaccine therapy in patients with renal cell carcinomaJoaquim Bellmunt, Antoni Ribas
Surgical Oncology Clinics of North America|November 21, 2007
Therapeutic cancer vaccinesLilah F Morris, Antoni Ribas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Targeting oncogenic drivers and the immune system in melanomaGrant A McArthur, Antoni Ribas
Nature|October 12, 2012
Cancer therapy: Tumours switch to resistAntoni Ribas, Paul C Tumeh
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumorsSanjiv S Agarwala, Antoni Ribas
Journal for Immunotherapy of Cancer|August 25, 2025
Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumorsKristin G Anderson, Antoni Ribas
Cancer Journal (Sudbury, Mass.)|January 24, 2017
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a BackboneSiwen Hu-Lieskovan, Antoni Ribas
Immuno-Oncology Technology|June 27, 2022
Gene editing: Towards the third generation of adoptive T-cell transfer therapiesCristina Puig-Saus, Antoni Ribas
Pageof 47

Showing results (21-30 of 467) with videos related to

Sort By:
Pageof 47
The Journal of Pathology|September 13, 2013
New drug targets in metastatic melanomaBlanca Homet, Antoni Ribas
Nature Reviews. Immunology|October 2, 2019
Tumour-intrinsic resistance to immune checkpoint blockadeAnusha Kalbasi, Antoni Ribas
European Urology|February 10, 2009
Editorial comment on: Vaccine therapy in patients with renal cell carcinomaJoaquim Bellmunt, Antoni Ribas
Surgical Oncology Clinics of North America|November 21, 2007
Therapeutic cancer vaccinesLilah F Morris, Antoni Ribas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Targeting oncogenic drivers and the immune system in melanomaGrant A McArthur, Antoni Ribas
Nature|October 12, 2012
Cancer therapy: Tumours switch to resistAntoni Ribas, Paul C Tumeh
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 17, 2010
Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumorsSanjiv S Agarwala, Antoni Ribas
Journal for Immunotherapy of Cancer|August 25, 2025
Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumorsKristin G Anderson, Antoni Ribas
Cancer Journal (Sudbury, Mass.)|January 24, 2017
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a BackboneSiwen Hu-Lieskovan, Antoni Ribas
Immuno-Oncology Technology|June 27, 2022
Gene editing: Towards the third generation of adoptive T-cell transfer therapiesCristina Puig-Saus, Antoni Ribas
Pageof 47